INDEX

Abandonment option valuation, 522, 535–536, 558–559
AB Astra/Merck, 117
Accounting:
  accrual, 301–302
  changes in, 320–322
  choice of system for and DAE valuation, 308–309
  clean surplus, 363
  consolidation, 370–371
  discovering poor, with accruals, 378–381, 382, 383
  pooling and purchase, 220
  for stock options, 415–419
  type of, and business type, 376
Accounting benefits of employee stock option plans, 441
Accounting earnings. See Earnings
Accounting method, FCF analysis as independent of, 354, 359
Accounting profit, 41
Accrual accounting, 301–302
Accruals:
  decomposing earnings, 381–385
  insurance companies and, 386
  mergers and acquisitions and, 386
  SEC enforcement actions and, 385
  use of to discover poor accounting, 378–381, 382, 383
Acquisitions:
  cost of capital for, 227–228
  FEVA model and, 236–237
  pooling accounting and, 220
Adjusted book value approach, 262–263
“Adjusted maturity” approach to ESO valuation, 468
Adjusted present value (APV) method, 267–268
Affordable dividends:
  book value and economic value weights, 101–102, 103
  conventional dividends compared to, 96–101, 102–103
  overview of, 94–96
Agouron Pharmaceuticals:
  methods for valuation of, 524–525, 577–583
  overview of, 575
  results of valuation of, 583–585
  Viracept drug, 574
Allied Chemical & Dye, 9–10
All-inclusive approach to reporting income, 309–310
Allocation of capital, 362–363
Amazon.com, 363, 364, 488–489, 525
American options, 493
America Online. See AOL
Amgen, 423
Amortization:
  earnings focus and, 352–353
  of goodwill, 220, 224
Analysis, methods of. See also Equity securities analysis; Free cash flow (FCF) analysis;
  Fundamental analysis; Quality of earnings analysis; Sensitivity analysis
  benefit-cost, 33–34
  cash flow, 349
  competitive strategy, 120, 136–138, 147
  decision tree, 492, 502–504, 577–580
  DuPont, 38, 341n24
  guideline multiples, 263–265
  guideline transactions, 265
  leveraged buyout, 268
  security, 1, 293–294
  simulation, 492, 500–501
  transactions, 265
Analysts, use of earnings in valuation by, 303–304, 327–337
Anticipated return ($r$) in FCF analysis, 355–356
Antikarov, Vladimir, 547–548
AOL, 376–377, 423, 490
Arbitrage, principle of, 545–546
Arbitrage opportunity, 513
Arbitrage pricing theory:
CAPM compared to, 113
equity securities analysis and, 121–122
Asset approach to estimating capital, 48, 50
Asset/cost approaches to valuation:
adjusted book value, 262–263
overview of, 261
replacement cost, 263
Asset life in CFROI, 58
Assets. See also Illiquid common stock;
Underlying assets
evaluating, 386–387
exit or salvage value of, 493
fair market value of, 260–261
net financing, 245, 248
net operating, 245, 248, 378
nondeprecating, in CFROI, 59
nonoperating, 107
passive financial, 350
return on, 37, 65
Assets in place, cash flows from, 221–222
Asset value, equity value compared to, 23–24
Asset-value factor in formula valuations, 8–9, 10
Assumptions, failure to meet, and real options valuation:
known and constant volatility, 539
lognormality, 537–538
minor assumptions, 539–540
overview of, 537
randomness, 538–539
AT&T, 314
At-the-money options, 411–413
Australia, tax laws in, 400
Available-for-sale marketable equity securities, 328–329
Bailey, Warren, 552
Balance sheet approach, 244
Bankruptcy costs, present value of, 232
Barrier option lattice model for valuing employee stock options, 466
Basic earning power ratio, 37, 65
Benchmark variables for stock price performance, 63–64
Benefit-cost analysis, techniques for, 33–34
Berger, Philip, 552
Bernstein, Richard, 224
Beta:
definition of, 52, 264
estimations for cost of equity, 217–219
in traditional valuation methods, 175
Bethlehem Steel, 8
Bettis, J. C., 467, 469, 470, 475, 476, 478
Bias in option-valuation models, 437–439
Bing, Ralph A., 8
Binomial models, 510–516, 556, 562–564, 580–583
Biotechnology companies, valuation of:
assumptions, 576–577
binomial-lattice method, 580–583
decision tree method, 577–580
overview of, 524–525, 573–574
results of, 583–585
Bizjak, J. M., 467, 469, 470, 475, 476, 478
Black–Scholes model:
for employee stock options, 466
formula for, 493
modified, 434–435, 436–437
Nobel Prize for, 555
for non-dividend-paying stock, 418
for real options valuation, 556
for traded options, 428–429
variation including dividends, 275, 418–419
Black–Scholes option-pricing formula for call options, 504
Book capital, 224
Book value (BV). See also Price-to-book ratio
adjusted book value approach, 262–263
changes in, 381–382
description of, 157
as value driver, 392–393
Book value of equity approach to estimating capital, 48–49, 50
Book value of equity to market value of equity ratio (BV/MV), 39–40
Book value weights, 101–102, 103
Bottom-up approach to avoiding destruction of capital, 21–24
Brazil, Russia, India, and China (BRIC), as monetary epicenters, 21
Brown Shoe Company, 250–251
Burgstahler, David, 553
Busby, J. S., 554
Businesses. See Companies
Business model erosion, 23
Buy-side analysts, use of reported earnings by, 303, 327–337
BV. See Book value
BV/MV (book value of equity to market value of equity ratio), 39–40
Call options:
  binomial tree for, 515
  definition of, 493
  synthetic, 512
Cancellations and option exercise, 432
Capital. See also Cost of capital; Return on capital
  asset approach to estimating, 48, 50
  avoiding permanent impairment of, 18, 21, 25
  in calculation of economic profit, 48–51
  definition of, 48
  definitions of in valuation models, 248
  efficient allocation of, 362–363
  invested, 8, 354, 355
Capital asset pricing model (CAPM):
  cost of equity and, 79–82, 212, 264
  equity securities analysis and, 121–122
  finite-growth model and, 177
  general risk premium estimation and, 110
  limitations of, 113
Capital-budgeting techniques, 33–34
Capital deficiency or surplus, 108
Capital expenditures, maintenance and growth of, 277
“Capital invested game” and EVA, 225
Capitalization rate in discounted cash flow approach, 111
Capital structure, vulnerability from, 23–24
CAPM. See Capital asset pricing model
Carpenter utility-based model of rational early exercise, 475, 478, 479
Cash, in investment approach, 20, 27
Cash-driven valuation models. See Discounted cash flow (DCF) approach
Cash earnings valuation models, rush to, 296
Cash flow. See also Discounted cash flow (DCF) approach
  from assets in place, 221–222
  assumptions of, 540
  exercise of stock options and, 429–430
  information content of, compared to earnings, 301–303
  manipulation and timing of, 340n18
  option tax effects on, 423–427
  uncertainty and, 495
  in valuation models, 245–247
  as value driver, 389–390, 402–403
Cash flow analysis, 349. See also Free cash flow (FCF) analysis
Cash flow approach to stock options, 413–415
Cash flow return on investment (CFROI):
  HOLT method, 57–61
  origins of, 32
  “Cash is king” perspective, 340n17, 350–351
Cash operating taxes, 47–48
CFROI (cash flow return on investment):
  HOLT method, 57–61
  origins of, 32
Circularity problem, solution for, 232–235
Cisco Systems, 172, 423, 490
Clayton, Matthew, 553
Clean surplus accounting, 363
Clean-surplus relation, 256, 257n6
Clinical trials of drugs, 575
Clinton administration, 119
Colgate-Palmolive Company, 357, 358
Commodity businesses, valuation of, 22–23
Common stock, cost of, 79–82
Companies. See also Biotechnology companies, valuation of
  commodity, valuation of, 22–23
  comparable, selection of, 252–255, 263–264
  discounted cash flows of, 25
  equity as residual claim on, 23–24
  franchise, valuation of, 22–23
  high-P/E, 185
  insurance, and accruals, 386
  management of, 24
  misvaluation of, 555
Companies (continued)
opportunistic earnings management by, 328, 335
overpayment for, 22–23
perpetuity assumption for, 23, 26
"recovering dogs," 250
start-up, and FEVA model, 237–238
terminal phase of, 189–190, 205
using stock to fund CAPEX, 277
value-enhancing actions of, 220–223
value-neutral actions of, 220
Company-specific risk premium, 110
Comparables, finding, 252–255, 263–264
Comparative advantage, 34
Comparative analysis in ROE performance, 146
Comparative statistics, 507
Compensation. See also Employee stock options
design of, 441–442
incentive effects and, 444–446
performance and, 33
Competition. See also Franchise valuation under Q-type competition
in pharmaceutical industry, 117, 118–119
Q-type competitive equilibrium, 192–193
Competitive advantage, 22, 23, 34, 56, 84,
136, 178–187, 210, 308, 386
Competitive equilibrium, 192–193,
307–308
Competitive strategy analysis framework, 120,
138–140, 147
Compound options, 493
Comprehensive income, reporting,
322–323, 324–326, 335–337
Computation of present value, 6
Conditional NPV:
in DCF analysis, 496–498
in option valuation, 504
in simulation analysis, 500–501
Consolidation accounting, 370–371
Consolidation in pharmaceutical industry, 118
Constant-earnings model, formula for,
191, 198
Constant growth DDM, 271–273
Contingency claims approach, 244,
274–275
Contingent claims approach to valuation,
261–262, 274–275
Contingent liability, valuing, 114
Continuing operations, income from, 312
Continuing value in FCF analysis, 351
Contracts with related parties, 107
Contrarian approaches in valuation models, 157
Controlling interest, valuing, 276
Conventional dividend approach, affordable dividends compared to, 96–101,
102–103
Copeland, Tom, 547–548
Cost of capital:
for acquisitions, 228
in calculation of economic profit, 51–54
cost of common equity, 79–82
cost-of-debt capital, 78
cost of preferred stock, 79
in DCF analysis, 497
definition of, 41
overview of, 78
volatility and, 533
weighted-average cost of capital, 82
Cost-of-debt capital, 78
Cost of equity:
in CAPM, 79–82, 264
estimations of, 211–219
Costs:
of common equity, 79–82
of financing, 222
of preferred stock, 79
transaction, assumptions of, 539–540
Counterparty risk and hedging with options, 20
Country risk premiums, estimation of,
213–215
DAE (discounted abnormal earnings) valuation framework, 300–301, 302,
306–309, 335. See also Economic value added
Daily returns, use of in estimation of stock return volatility, 285
DCF. See Discounted cash flow (DCF) approach
DDM. See Dividend discount model
Debt-to-capital ratio, 276–277
Decay model, 194–196, 197, 201–202
Decision tree analysis, 492, 502–504,
577–580
Decomposing earnings, 381–385
Deferral option valuation, 521–522
Deflation and democracy, 18
### Index

**Dell Computer Corporation:**
- cash flows, 424–426
- consolidated statement of cash flows, 456–457
- consolidated statement of financial position, 454–455
- consolidated statement of income, 455–456
- consolidated statement of stockholders equity, 458
- current valuation of, 490
- financial statement of, 424
- footnote disclosure, 419–420, 424
- future option grants, 421–422
- income statement, 329
- modified Black–Scholes model and, 434, 435
- NQOs of, 423
- option exercise and, 429–430
- selected footnotes, 459–461
- value of outstanding options, 420–421

**Depreciation:**
- earnings focus and, 352–353
- economic estimates of, 369
- Krispy Kreme Doughnuts and, 376
- Netflix and, 376–377
- operating income after, 42–43

**Dichev, Ilia**, 553

**Dilution and employee stock option plans**, 446–448

**Direct valuation methods:**
- forecast-cash-flow approach, 244–245
- overview of, 244
- terminal-value problem, 245–248

**Discontinued operations**, 316–320

**Discounted abnormal earnings (DAE) valuation framework**, 300–301, 302, 306–309, 335. *See also* Economic value added

**Discounted cash flow (DCF) approach:**
- adjusted book value and, 262–263
- capital expenditures and, 114
- cash flow estimation, 106–108
- challenges of, 210
- in Cisco Systems valuation, 525–528
- discount rate determination, 108–110
- to employee stock option plans, 450–451
- estimation issues in, 211–219
- EVA compared to, 225–227
- flexibility and, 556
- formula for, 105–106, 210
- free cash flow and, 246
- historical earnings and, 364–365
- intrinsic value calculation, 120–122
- in Merck valuation, 122–123
- minority-interest and controlling-interest values, 112
- minority valuation and, 113
- MM approach, EVA, and, 232–235
- multistage, 140–141
- net present value and, 496–498
- operating cash flow, net income, and, 113
- overview of, 85n7, 105, 112, 244–245, 487
- range of discount rates used in, 112
- real options and, 555–556
- risk-free rate and, 113
- single-stage constant-growth, 140
- as subjective, 113
- two-stage model for calculating intrinsic value, 148
- valuation of investment projects and, 487–488
- value enhancement in, 219–220

**Discount factor (r) in FCF analysis**, 351, 355–356

**Discount rate:**
- components, 109–110
- definition of, 108
- external factors in, 108
- growth patterns and, 182–183, 184
- internal factors in, 108–109
- range and application of, 175–176
- two-stage DDM and, 166–167, 168, 169

**Discounts:**
- for illiquidity, 286–288
- for nonmarketability, 281

**Dividend discount model (DDM):**
- cash flow analysis and, 349
- cash flow and, 246
- for companies paying no dividend, 175
- constant growth DDM, 271–273
- earnings-based models derived from, 306
- free cash flow analysis and, 350
- as income approach to valuation, 270
- Modern Portfolio Theory and, 100
- normalized earnings in, 175
- overview of, 93–94, 244–245
- as traditional valuation method, 158
Dividend growth models, 96
Dividends, affordable:
  book value and economic value weights, 101–102, 103
  conventional dividends compared to, 96–101, 102–103
  overview of, 94–96
Dividends per share (DPS):
  definition of, 404
  earnings per share compared to, 398–401
Dividend valuation model (DVM), 79–80, 82
Dodd, David, 1, 2, 381
Dow Chemical, 8
Dow-Jones Industrial Average, 8–16, 252
DPS (dividends per share):
  definition of, 404
  earnings per share compared to, 398–401
Drug development, 574, 575, 576–577
Du Pont (company), 13
DuPont analysis, 38, 341n24
DuPont/Merck venture, 116
DuPont ROE decomposition approach, 117, 119, 120, 139, 152–153
DVM (dividend valuation model), 79–80, 82

Early exercise of stock options, 429–434, 466–467. See also Voluntary early exercise boundary
Earnings. See also Earnings-based models;
  Earnings management; Future earnings;
  Price-to-earnings ratio; Quality of earnings analysis; Reporting income classified income statements, 309–312
decomposition of, 381–385
definition of, 337–338
determinants of price reaction, 299
free cash flow compared to, 352–354
historical, definition of, 364–365
information content of, compared to cash flows, 301–303
long return intervals and, 299–300
measures of, 363–366
persistent components of, 365–366
policy implications of measures of, 370–371
pro forma, 361–362, 363–364, 365, 369
quality of, 7–8, 361–363
relevance of, to valuation, 296–297, 304
reporting of, 304–305
security prices and, 297–301
unexpected, and stock-price changes, 297–299
use of, in valuation, 303–304, 327–337
as value driver, 389–390, 392–393, 402–403
Earnings-based models. See also Discounted abnormal earnings (DAE) valuation framework
  benefits of, 334–335
  free cash flow models compared to, 305–309
Earnings before interest and taxes (EBIT), 22–23
Earnings before interest, taxes, depreciation, and amortization (EBITDA), 176, 392–393
Earnings management:
  definition of, 344n39
  opportunistic, 328, 335
Earnings measures, tests of quality of:
  comparison of methods, 367–368
  component data, 369–370
  economic earnings measures, 368–369
  information content method, 367
  predictive ability method, 367
  value relevance method, 366–367
Earnings per share (EPS):
  absolute valuation performance of forecasts of, 401–402
  calculation of intrinsic value using, 150
  definition of, 403
  dividends per share compared to, 398–401
  as estimate of cash flow per share, 278
  operating cash flow compared to, 397
  as value drivers, 392–393
Earnings power duration, 23
Earnings quality analysis. See Quality of earnings analysis
Earnings response coefficient (ERC), 299
Earnings surprise, 156, 377
eBay, 273–274
EBIT (earnings before interest and taxes), 22–23
EBITDA (earnings before interest, taxes, depreciation, and amortization), 176, 392–393
EBO (Edwards-Bell-Ohlson) model, 244–245, 248, 249
Economic capital expenditures, 114
Economic earnings measures, 368–369
Economic profit. See also Economic value added
accounting profit compared to, 41
calculation of, 42–54
capital and, 48–51
cash operating taxes and, 47–48
challenges applying, 56–57
cost of capital and, 51–54
estimating, 35
net present value and, 41–42
NOPAT, 42–46
overview of, 40–41
performance and, 54–55
return on capital and, 51
stock price performance and, 65–66, 70
Economic profit model, 247, 248
Economic value added (EVA). See also Profit, economic
cautions for, 225
DCF compared to, 225–227
formula for, 230–231
increases in, 228
MM approach and, 233–235
origins of, 32
overview of, 35, 224–225, 244–245, 369
reconciling market value added with,
55–56
Economic value weights, 101–102, 103
Edwards-Bell-Ohlson (EBO) model,
244–245, 248, 249
Embedded cost of capital, 78
Emerging markets, betas for, 218
Empirical studies. See also Earnings measures,
tests of quality of: Experiment in use of reported earnings in valuation
of quality of company earnings, 366–370
of real options valuation, 551–554
of stock price performance, 67–74
Employee stock options (ESOs). See also
Voluntary early exercise boundary
accounting for, 415–419
compensation design and repricing,
441–442
consequences of for valuation, 413–415
DCF analysis and, 450–451
Dell example, 419–422
determination of option grants, 443
dilution and, 446–448
diversification and, 439
eye exercise modeling, 466–467
future issues with, 453
growth in importance of, 410
implications of research on, 451–453
incentive benefits, accounting benefits, and, 441
incentive effects, 444–446
lattice models for valuing, 466–467, 475–479
market valuation of, 448–450
origins of, 410–411
patterns of option exercise, 428–434,
465–466, 479–480
“representative investor” approach to valuing,
467, 472–473
repurchases, dilution, and, 444
risk aversion, incentive effects, and, 439
shift to restricted stock, 454
tax issues, 422–428
typical features of, 411–413
valuation models, 434–439
volatility and, 439–441
Enron, 369–370, 387
Enterprises, ownership of, 21. See also Companies
Enterprise value, definition of, 278n1
Enterprise value to earnings before interest,
taxes, depreciation, and amortization (EV/
EBITDA), 244
Enterprise value to sales (EV/S), 251
Entropy and business model erosion, 23
EPS. See Earnings per share
Equity, 23–24. See also Return on equity
Equity–r in FCF analysis, 356–357
Equity securities analysis. See also Merck & Company; Pharmaceutical industry
plan for, 119–125
qualitative factors of, 153–154
quantitative factors of, 152–154
research for, 116–119
Equity value, formula for, 96
ERC (earnings response coefficient), 299
ESOs. See Employee stock options
Estimation issues:
cost of equity, 211–219
nominal and real valuation, 211
European options, 493, 540
EVA. See Economic value added
EV/EBITDA (enterprise value to earnings before interest, taxes, depreciation, and amortization), 244
EVPV (expected net present value), formula for, 577–578
EV/S (enterprise value to sales), 251
Ex ante value, 425
Excess return in DCF analysis, 219
Executive compensation and performance, 33
Exercise-date accounting, 423
Exercise of stock options:
assumptions about, 428–429
empirical evidence of early exercise, 430–434
timing of, 429–430
Exercise price:
definition of, 493
in real options valuation, 541–542
Exit value, 493
Expansion options, valuation of, 518–521, 528–531
Expectational models, 156–157
Expected earnings, 252
Expected growth rate, 222
Expected net present value (EVPV), formula for, 577–578
Expected option life assumption, 438
Expected rates of return, conventional compared to affordable dividend approaches, 100–101
Expensing options, arguments against, 417
Experiment in use of reported earnings in valuation:
analysis of stock-price estimates, 332–334
case materials, 329–331
conclusions from, 334–335
follow-up study, 335–337
objectives and procedures, 328–329
overview of, 327–328
participants, 332
Ex post value, 425
Extraordinary items, income from, 319–320
Exxon Corporation, 319, 320
Fade, buying businesses priced for, 23
Fairly priced companies, 172
Fair market value:
definition of, 261
estimating, formula for, 106
FASB. See Financial Accounting Standards Board
FCF. See Free cash flow
FCF analysis. See Free cash flow (FCF) analysis
FCFE (free cash flow to equity) approach, 269–270
FCFF (free cash flow to firm) approach, 266–268
Federal Reserve, monetary policy of, 21
FEVA (financial and economic value added):
derivation of formula, 239–241
implementation of, 235–238
Finance balance sheet, 260
Financial Accounting Standards Board (FASB):
Accounting for Stock-Based Compensation, 417–418
Emerging Issues Task Force of, 314
“Reporting Information about the Financial Performance of Business Enterprises,” 362, 370
Share-Based Payment, 480
Financial analysis, challenges of, 554–555
Financial and economic value added (FEVA):
derivation of formula, 239–241
implementation of, 235–238
Financial options:
real options compared to, 494
valuation of, 510–516
volatility and value of, 507
Financial risk and discount rate, 109
Financial statements, rules guiding preparation of, 295
Finite-growth model:
application of, 178
comparison of new model with Gordon and Gordon model, 186–187
evaluation of reasonableness of P/E, 183–185
of Gordon and Gordon, 178–179, 216
market expectations and, 181–183
overview of, 177, 185–186
partial reinvestment of earnings in positive-NPV projects, 180–181
total reinvestment of earnings in positive-NPV projects, 179–180
First Eagle:
asset buying of, 23–24
gold and, 20
margin of safety and, 26
mind-set of, 17, 18–19
portfolios of, 25
track record of, 24–25
Flexibility options, 488, 495
Food and Drug Administration, 119
Forecast-cash-flow approach, 244–245
Forecasting:
  earnings-based models and, 334–335
  free cash flows, 351
  marginal tax rate, 427–428
  measures of earnings in, 363
  option grants, 443
  overview of, 243–244, 256–257
Formula valuations:
  based on market price, 10, 13–16
  based on past performance, 7–10, 11–12
Franchise businesses, valuation of, 22–23
Franchise factor model, 234, 240
Franchise slides, 190
Franchise P/E, 84
Franchise rides, 190
Franchise slides, 190, 192, 193
Franchise valuation under Q-type competition:
  competitive equilibrium, 192–193
  general decay model, 194–196, 197, 201–202
  overview of, 205
  PV-equivalent ROE, 196–198
  single-phase no-growth model, 191
  two-phase growth model, 198–204
Franchise value, 35
Free cash flow (FCF):
  ability of current to predict future, 302
  accruals and, 378
  capital expenditures, maintenance and growth of, 277
  definition of, 210, 245
  earnings compared to, 305–309
  estimation of, 106–108
  forecasting, 351
  off-balance-sheet items and, 276
Free cash flow (FCF) analysis:
  applications of, 359
  calculating levered r, 356
  changes in working capital and, 359
  earnings focus compared to, 352–354
  estimating anticipated growth in FCF, 355
  estimating current FCF, 354
  example of, 357, 358
  implementation problems with, 351–352
  as independent of accounting method, 354, 359
  inferring expected return on unlevered firm, 355–356
  issues in, 351
  justification for, 350–351
  limitations and benefits of, 357
  overview of, 349–350
  relating Equity-r to risk, 356–357
  for stock valuation, 354–357
Free cash flow generation, 24, 26
Free cash flow to equity (FCFE) approach, 269–270
Free cash flow to firm (FCFF) approach, 266–268
Fundamental analysis:
  of financial statements, 302–303
  market efficiency and, 375
  purpose of, 156
  traditional valuation methods in, 164–172
  two-stage dividend discount model, 164–167, 168, 169
  valuation, 167–172
Fundamental value and real options, 536
Future earnings:
  challenges of estimating, 5–6
  methods for estimating, 6–7
  as predicted by market price, 10, 13–16
  as predicted by past performance, 7–10, 11–12
Future returns and option exercise, 433–434
GAAP. See Generally accepted accounting principles
The Gap, 224
General decay model, 194–196, 197, 201–202
General Electric, 13
Generalized DDM, 158
Generally accepted accounting principles (GAAP):
  capital expenditures, 114
  flexibility in application of, 320
  latitude allowed by, 295
  measures of earnings, 364, 370
  General risk premium, 109–110
  Generic drugs, regulatory approval process for, 118
  Goals of investors, 17–18
  Going-concern value, 262
Gold:
in investment approach, 20
value of, 26-27
Goodwill, amortization of, 220, 224
Goodyear, 10
Gordon, J., 177, 178-179, 186-187
Gordon, M., 1, 177, 178-179, 186-187
Gordon and Gordon model, 178-179, 186-187, 216
Graham, Benjamin, 1, 2, 381
Graham, John, 427-428
Grant-date accounting of option expense, 416, 423
Gross cash flow in CFROI, 57-59
Gross cash investment in CFROI, 59
Growth characteristics of model portfolios, 161-163
Growth duration, formula for, 171
“Growth game” and EVA, 225
Growth models. See also
Finite-growth model
dividend, 96
in terminal phase, 205
three-stage, 96
two-phase, 198-204
Growth options:
market capitalization and, 366
valuation of, 518-521, 528-531
Growth rates and two-stage DDM, 164-166, 168, 169
Growth stocks, 172, 174
GTE Corporation, 321
Guideline multiples analysis, 263-265
Guideline transactions analysis, 265
Harmonic means, 252, 391
Harnischfeger Industries:
extraordinary item disclosure, 319, 321
income statement, 310, 311
nonrecurring item disclosure, 312, 313-314
restructuring charge, 313, 314
Hayn, Carla, 553-554
Health care reform, 116, 117
Heath, C., 433
Hedge funds, liquidity restrictions on, 288
Hedging:
assumptions of, 545-547
with options, and macro risk, 20
Hershey Foods Corporation:
capital calculation for, 50
cash operating taxes of, 47-48
CFROI calculation for, 58-60
cost of capital calculation for, 51-54
economic profit of, 54-55
market value added for, 55
NOPAT calculation for, 43-46
return on capital calculation for, 51
“High flyer” stocks, 172, 173
High-growth periods, lengthening, 222
High-P/E companies, 185
Historical earnings, definition of, 364-365
Historical risk premiums and cost of equity estimations, 212-219
Historical stock market return:
data on, 110
extrapolating from, 153
volatilities, 282
Historical volatility approach, 543-544
H-model, 121, 124, 125, 141, 152
Hokie Company case example:
binomial model for, 562-564
cash flow for, 497
DCF analysis for, 496-498
decision tree analysis of, 502-504
investment opportunity for, 495-496
option valuation for, 504-509
sensitivity analysis of, 499-500
simulation analysis of, 500-501
Holding gains on securities, 328-329
HOLT method, 57-61
Homer, Sidney, 1
Hong Kong, tax laws in, 400
Howell, Sydney, 553-554
Huddart, Steven, 430-433, 435, 441
Huddart model, 435-436
Hull, J., 466, 469, 480
HW (Hull and White) model of ESO valuation, 466, 469, 480
I/B/E/S International Summary files, 393
IBM, 95, 312, 490
Identification of unusual items, 313-314
Illiquid common stock:
case study, 286-288
options-based framework for, 280-282
stock return volatility, 282-286
valuing, 279-280, 288
Implied equity premium, estimating, 215–217, 227
Implied volatility approach, 543, 544
Incentive benefits of employee stock options, 441
Incentive effects of employee stock options, 439, 444–446
Incentive stock options (ISOs), 422
Income. See Comprehensive income, reporting; Earnings; Reporting income
Income approaches to valuation:
  dividend discount model, 270–274
  free cash flow to equity, 269–270
  free cash flow to firm, 266–268
overview of, 261
Income statements, 309–312
Industry multiples, 389–390. See also Multiples-based approaches
Information content method, 367, 368
Inputs for real options valuation, difficulty of estimating, 540–545, 556–557
Institutional Shareholder Services (ISS), 469
Insurance companies and accruals, 386
Intangibles, 157
Interest expense, implied, 45
Internal rate of return (IRR):
  for benefit-cost analysis, 34
  CFROI compared to, 57
  net present value compared to, 42, 83
quality of earnings and, 378
International Nickel, 10
International Paper, 164, 165, 166, 167
Interquartile (IQ) range, 395
Intrinsic value:
  calculating, 147–148
  calculating with H-model, 151
  calculating with P/E and EPS, 150–151
  calculating with two-stage DCF model, 148
  market price as proxy for, 403
  sensitivity analysis, 149
of stocks, 243
Inverse of price/cash-flow ratio plus growth method, 109–110
Invested capital:
  definition of, 354
  estimating growth in, 355
  rate of earnings on, 8
Investigational New Drugs, 574–575
Investment projects:
  with abandonment option, binomial trees for, 523
  binomial trees for, 516, 518
  with deferral option, binomial trees for, 522
  with growth option, binomial trees for, 519
  valuation of, 487–488
Investment value, definition of, 261
Investors:
  caveats for EVA, 225
  goals of, 17–18
  “representative” and ESO valuation, 467, 472–473
IQ (interquartile) range, 395
IRR (internal rate of return):
  for benefit-cost analysis, 34
  CFROI compared to, 57
  net present value compared to, 42, 83
  quality of earnings and, 378
ISOs (incentive stock options), 422
ISS (Institutional Shareholder Services), 469
Jägle, Axel, 553–554
Johnson & Johnson/Merck venture, 116
Joint ventures in pharmaceutical industry, 118
Judgment in determining value:
  choice of earnings measures, 366
  insight into factors affecting, 303–304
  sector composition, 159–160
  traditional methods and, 155, 172, 175
Kimberly-Clark Corporation, 353
Knight, Frank, 2
Krispy Kreme Doughnuts, 376
$L$ (fixed maximum anticipated life), 467
$L$ (fixed maximum anticipated life) model of ESO valuation, 468, 472–479
Lang, Mark, 427–428, 430–433, 435, 441
Lattice models:
  for valuing biotechnology companies, 580–583
  for valuing employee stock options, 466–467, 475–479
Learning options, 525, 527
Lehman Brothers, 465–466
Leibowitz, Martin, 1
Lemmon, M. L., 467, 469, 470, 475, 476, 478
Level of value, defining, 260
Leveraged buyout analysis, 268
Liquidity:
of hedge funds, 288
value of, 280–282
Lognormality, assumption of, 537–538
Longstaff, F. A., 280
Longstaff model, 280–281, 282, 285, 286
Loss companies, 253
Losses and earnings focus, 353
Lucent Technologies, 423
$M$ (fixed multiple of strike price), 466, 467
$M$ (fixed multiple of strike price) model of ESO valuation, 469, 470, 472–479
MacMillan Bloedel, 316
Macro risk, dealing with, 19–20
Management:
of earnings, 328, 335, 344n39
of enterprises, 24
expenses written off by, 176
goal of, 62
value-based, 369
value created by, 33–35
Management discussion and analysis (MD&A) sections of annual reports, 313
Mandatory accounting changes, 320–322
MAR (market model-adjusted return) variable, 63–64, 71–72, 73–74, 75–76
Marginal cost of capital, 78
Margin of safety:
asset value and, 23–24
business model erosion and, 23
business valuation and, 22–23
combining elements of, 24–25
macro risk and, 18–19
management of enterprises and, 24
as mind-set, 17
overview of, 26
seeking, 21–24
uncertainty and, 18–19
Market approaches to valuation, 261, 263–265
Marketed asset disclaimer, 547–548
Market expectations and finite-growth model, 181–183
Market model-adjusted return (MAR) variable, 63–64, 71–72, 73–74, 75–76
Market multiples:
$E/V/S$, 251
$P/B$, 249, 250
$P/E$, 249–251
selection of comparable companies, 252–255
Market price:
elements of, 36
formula valuation based on, 10, 13–16
as proxy for intrinsic value, 403
Market risk premium, 52, 57, 81
Market share, increases in, 223
Markets outside U.S., risk premiums in, 213–215
Market/strike ratio, 431–432
Market valuation of options, 448–450
Market value added (MVA):
challenges applying, 56–57
overview of, 35, 55
reconciling economic value added with, 55–56
stock returns compared to, 77–78
Market value of underlying assets, 540–541
Markowitz, Harry, 1
MD&A (management discussion and analysis) sections of annual reports, 313
Mean-reversion approaches in valuation models, 157
Measures of earnings:
comparison of methods, 367–368
component data, 369–370
economic earnings measures, 368–369
information content method, 367
overview of, 363–366
predictive ability method, 367
value relevance method, 366–367
Measures of firm performance, traditional, 37–40. See also Measures of value added
Measures of option expense, 416–417
Measures of value added. See also Economic value added; Profit, economic benefits of, 61–62
challenges applying, 56–57
Holt CFROI, 57–61
limitations of, 61
market value added, 55–56
overview of, 40
Merck & Company:
- comparative financial ratios, 121
- competitive strategy analysis of, 145
- description of, 115
- financial data, 128–133
- intrinsic value calculation, 147–148
- outlook for future, 117
- position on health care reform, 117
- price performance, 125
- pricing and demand for pharmaceuticals, 118–119
- qualitative analysis of, 153–154
- ROE decomposition analysis, 120, 153
- ROE performance evaluation, 145–146
- strategic objectives, 116–117
- structural reorganization, 116–117
- Value Line on, 123

Mergers and acquisitions (M&A). See also Acquisitions
- accruals and, 386
- gross cash flow and, 24
- Microsoft Corporation, 164, 165, 166, 167, 172, 423
- Miller, M., 231. See also Modigliani and Miller (MM) approach
- Minority interest, valuing, 276
- Model risk, 536–537
- Models. See also specific models
different results yielded by, 229
failure to meet assumptions of, 537–540
as snapshots in time, 172, 175
Modern Portfolio Theory and dividend
discount models, 100
Modified Black–Scholes model, 434–435, 436–437
Modigliani, F., 231
Modigliani and Miller (MM) approach, 231, 232–235
Moel, Alberto, 553
Momentum measures in expectational
models, 156
Money, price of, as fake, 18
μ (mu, fixed proportion) model:
accuracy of, 479–480
comparison to L and M models, 472–479
overview of, 466, 467, 469–470
proof, 471–472
proposition, 470–471

“Multiple of strike price” approach to ESO valuation, 469, 470
Multiples-based approaches:
dominance of earnings in U.S. sample, 392–393
earnings compared to cash flow in, 402–403
EV/S, 251
forecasting in, 244
guideline multiples, 263–265
historical earnings and, 365
international results from, 395–402
international sample for, 393–395
overview of, 255–256, 390–392
P/B, 249, 250
P/E, 249–251
selection of comparable companies, 252–255
Multistage DCF model, 140–141
Multistage DDM, 158
MVA. See Market value added

NASDAQ 100, 427–428
Nasdaq Composite Index, 168, 170, 171, 283
Net book value, 300–301, 339n8
Net cash flow, estimation of, 106–108
Net financing assets (NFA), 245, 248
Netflix, 376
Net income, accrual-basis, 302
Net operating assets (NOA), 245, 248, 378, 382
Net operating profit after taxes (NOPAT), 42–46, 354
Net present value (NPV):
in benefit-cost analysis, 33–34
Conditional, 496–498, 500–501, 504
in DCF analysis, 496–498
economic profit and, 41–42
for investment projects, 35
IRR and, 42, 83
strategic, 492–493, 506
New-economy stocks, 255, 296
New molecular entities (NMEs), 574, 575
New York Stock Exchange (NYSE), stock
return volatilities, 283
NFA (net financing assets), 245, 248
Nike, 250–251, 304
NMEs (new molecular entities), 574, 575
NOA (net operating assets), 245, 248, 378, 382
Nominal valuation, 211
Nondepreciating assets in CFROI, 59
Nonoperating assets, 107
Nonparametric correlations, 88n52
Nonqualifying stock options (NQOs), 422–423
Nonrecurring income, 107, 312–314
NOPAT (net operating profit after taxes), 42–46, 354
Normal growth periods, projections for, 96–97
Normalized earnings in DDM approach, 175
Normal profit, 84
NPV. See Net present value
NQOs (nonqualified stock options), 422–423
OCF (operating cash flow), 392–393, 397
OE (operating expenses), 245
Ofek, Eli, 552
Off-balance-sheet items in free cash flow analysis, 276
One-time charges, adjustments for, 224
OPEB (other postemployment benefits), 321
Operating capital, 50
Operating cash flow (OCF), 392–393, 397
Operating cash flow per share, definition of, 403
Operating expenses (OE), 245
Operating income after depreciation, 42–43
Operating leases:
  of The Gap, 224
  present value of, 46
Operating profit margin, 251
Operating revenue (OR), 245
Operating risk and discount rate, 109
Opportunistic earnings management by companies, 328, 335
Option-pricing (option valuation) method:
  assumptions of, 551
  employee stock options, 426
  as example of contingent claims approach, 262, 274–275
  Huddart model, 435–436
  investigations of, 436–437
  modified Black–Scholes model, 434–435
  potential for bias in, 437–439
  real options valuation using, 516–523
  underlying asset value and, 535–536
  volatility in, 543–544
Option-pricing theory:
  overview of, 509–510
  real options and, 491
Options. See also Employee stock options;
  Financial options; Growth options;
  Real options
  American, 493
  at-the-money, 411–413
  call, 493, 515
  compound, 493
  European, 493, 540
  expansion, valuation of, 518–521, 528–531
  expensing, arguments against, 417
  flexibility, 488, 495
  hedging with, and macro risk, 20
  learning, 525, 527
  put, 493, 513
  repricing, 441–442
  repurchases of, to avoid dilution, 444
  scale-up, 525, 527
  scope-up, 525, 527
  synthetic call, 512
  value of, and volatility, 507–508, 509
Options-based framework for valuing illiquid common stock, 280–282
Option to contract, 559–560
Option to default, valuation of, 522–523, 558–559
Option to shut down, 560–562
Option valuation, 504–509
OR (operating revenue), 245
Other postemployment benefits (OPEB), 321
Overpayment for businesses, 22–23
Overpriced companies, 172
Overpriced high-P/E stocks, 185
Owner compensation, 107
Paddock, James, 551–552
Passive approach to investing, 25
Passive financial assets, 350
Past earnings history:
  formula valuation based on, 7–10, 11–12
  historical earnings, definition of, 364–365
  relationship to future earnings, 6
Pay and performance, 33
Payback period method, net present value compared to, 42
P/B (price-to-book ratio):
  as multiple-based approach, 249, 250
  overview of, 157
  as relative valuation method, 244
  as valuation tool, 144
P/CF (price-to-cash-flow) ratio, 391
P/E. See Price-to-earnings ratio
Peer analysis in ROE performance, 145
Peer-based relative valuation tools, 249–252
PeopleSoft, 172
Performance evaluation. See also Measures of value added; Stock price performance controllable and uncontrollable aspects of investments, 36
criteria for, 36
overview of, 33
return-on-investment ratios, 37–38
Tobin’s q, 38–40
traditional measures of performance, 37–40
value creation and, 33–35
Perpetuity assumption for businesses, 23, 56
Persistence:
of earnings, determining, 323, 327
of stock return volatility, 283–284
Persistent components of earnings, 365–366
Pharmaceutical industry. See also Agouron Pharmaceuticals; Merck & Company
comparative financial ratios, 121
competitive structure of, 145–146
drug development, 574–575
five-year earnings growth rate forecasts, 121
fundamentals of, 117
marketing pharmaceuticals, 142–143
price performance, 125
pricing and demand for pharmaceuticals, 118–119
research and development expenses of, 308
statistical data, 132–136
PIG (price-implied growth) rate, 168–169, 171
Pitts, C.G.C., 554
Pooling accounting, 220
Popper, Karl, 21
Porter, Michael E., 136
Postemployment benefits, 321
Postemployment expenses and earnings focus, 353
“Preannouncing” earnings, 296–297
Predictive ability method, 367
Preferred stock, cost of, 79
Preselling products, 341n25
Present value (PV):
of expected future payoffs, 243
in free cash flow analysis, 350
of free cash flows, formula for, 355
Preservation of purchasing power, 21
Price-implied growth (PIG) rate, 168–169, 171
Price reaction, determinants of, 299
Price-to-book ratio (P/B):
as multiple-based approach, 249, 250
overview of, 157
as relative valuation method, 244
as valuation tool, 144
Price-to-cash-flow (P/CF) ratio, 391
Price-to-sales ratio (P/S), 144, 157–158, 244
Price-to-revenue ratio, 265
Profit. See also Profit, economic
accounting profit compared to, 41
calculation of, 42–54
capital and, 48–51
cash operating taxes and, 47–48
challenges applying, 56–57
cost of capital and, 51–54
estimating, 35
net present value and, 41–42
NOPAT, 42–46
overview of, 40–41

Profit, economic (continued)
performance and, 54–55
return on capital and, 51
stock price performance and, 65–66, 70
Pro forma earnings, 361–362, 363–364, 365, 369
Property rights, respect for, 27
"Proportion of option value captured"
approach to ESO valuation, 469–472
Proxy for q ratio, 39
Prudent man rule, 289n8
P/S (price-to-sales ratio), 142, 157–158, 244
Purchase accounting, 220
Purchasing power, preservation of, 21
Pure plays, 264
Purpose of valuation, specifying, 260–261
Put options, 493, 513
PV. See Present value
PV-equivalent ROE, 196–198
Q-type competitive equilibrium, 192–193.
See also Q-type competition
Qualcomm, 423
Qualitative factors of equity securities analysis, 153–154
Quality of earnings:
empirical tests of, 366–370
evaluation of, 7–8, 361–363
Quality of earnings analysis:
accruals example, 378–381, 382, 383
decomposing earnings, 381–385
defining earnings quality, 378
earnings surprises, impact of, 377
overview of, 375–376, 385
purpose of, 376–377
Quality-of-earnings ratios, 353–354
Quantitative factors of equity securities analysis, 152–153
Quigg, Laura, 552
Q-values, 38–40
R (anticipated return) in FCF analysis, 355–356
R (cost of capital for project), 90n71
Randomness, assumption of, 538–539
R&D. See Research and development (R&D) expenses
Real options, See also Real options valuation
background and methodology of, 491–494
definition of, 485, 486
financial options compared to, 494
studies in, 492
in technology sector, 488–491
Real options valuation:
of Agouron Pharmaceuticals, results of, 583–585
applying, 524–525, 557
binomial example of Hokie Company, 562–564
binomial-lattice method, 580–583
of biotechnology companies, 573–574, 585
Cisco Systems case study, 525–528
complications from internal and external interactions, 535–536
criticism of, 557
decision tree method, 577–580
definition of, 488
direct and indirect tests of, 551–553
examining sensitivities, 531–533
failure to meet assumptions, 537–540
framework for, 509–523
gathering information, 528–529
inputs for, 540–545, 556–557
in investment projects, 558–562
limitations of, 534–535, 556
model risk, 536–537
Nole case study, 528–534
nontradability of underlying asset, 545–550
option to contract, 559–560
option to default, 558–559
option to shut down, 560–562
overview of, 494, 555–557
traditional valuation compared to, 494–509
use of, 553–555
valuing company without considering option, 529
valuing option, 529–531
Real valuation, 211
Recording option expense, 416–417
Reebok International, 250–251
Regression beta problem, solutions to, 218–219
Reinvestment of earnings in positive-NPV projects, finite-growth model for, 179–181
Index 605

Relative valuation methods, 244, 249–252
Replacement cost approach, 263
Reporting income:
accounting changes, 320–322
all-inclusive approach to, 309–310
comprehensive income, 322–323, 324–326, 335–337
from continuing operations, 312
discontinued operations, 316–319
extraordinary items, 309–312
model for, 305–309
overview of, 304–305, 323, 327
restructurings, 314–316, 353
unusual and nonrecurring items, 312–314

“Representative investor” approach to ESO valuation, 467, 472–473
Repricing options, 441–442
Repurchases of options to avoid dilution, 444
Research and development (R&D) expenses:
earnings focus and, 353
EVA and, 224
for new drugs, 574–575, 576–577
of pharmaceutical companies, 308
Residual income (RI), 247–248, 256–257, 341n22
Residual income model (RIM), 244–245, 246, 248, 256, 257
Restricted stocks, 288, 454
Restructuring charges, 314–317, 353
Return on assets, 37, 65
Return on capital:
in calculation of economic profit, 51
definition of, 42
stock price performance and, 66, 70, 77
Return on equity (ROE):
in DAE model, 308
definition of, 65
DuPont ROE decomposition approach, 119, 120, 139, 152–153
formula for, 37
growth-driven, 199–200
Merck case study, 145–147
P/B and, 157
PV-equivalent, 196–198
terminal, in Q-type competition, 200–204
Return on investment, 84. See also Cash flow return on investment
Return-on-investment ratios, 37–38
Revenue. See Earnings; Income; Profit
RI (residual income), 247–248, 256–257, 341n22
RIM (residual income model), 244–245, 246, 248, 256, 257
Risk. See also Risk-free rate; Risk neutral valuation; Risk premiums
counterparty, and hedging with options, 20
economic profit and, 51
equity, 494
expectations, performance characteristics of model portfolios, and, 163–164
macro, dealing with, 19–20
model risk, 536–537
operating, and discount rate, 109
relating Equity-r to, 356–357
stock options and willingness to take on, 445
uncertainty compared to, 2
Risk aversion and employee stock option plans, 439–441, 476–479
Risk-free rate:
assumptions of, 539
cost of equity capital and, 52
cost of equity estimations and, 212
definition of, 494
discount rate and, 109
in real options valuation, 542–543
“Risk game” and EVA, 225
Risk neutral probabilities, 517
Risk neutral valuation, 520, 545–547, 548–550, 581
Risk premiums, 212–219, 227
ROE. See Return on equity
ROE composition of model portfolios, 161
Sales-driven context for terminal phase, 190
Sales-driven franchise value. See Franchise valuation under Q-type competition
Salvage value, 493
SAR (size-adjusted return) variable, 64, 71–72, 73–74, 75–76
Scale-up options, 525, 527
SCE (statement of changes in equity), 335–337
Scenario analysis. See Sensitivity analysis
Scope-up options, 525, 527
Screening uses of traditional valuation methods:
growth characteristics, 161–163
risk, expectations, and performance, 163–164
ROE composition, 161
sector composition, 159–160
valuation, 160–161
Security analysis:
  central function of, 293–294
  history of, 1
Security market line, 272–273
Security returns, 39–40
Sell-side analysts, 303
Sensitivity analysis, 126, 149–150, 492, 499–500, 501
Shackelford, Doug, 427–428
Share price performance. See Stock price performance
Sharpe, Bill, 1
Siegel, Daniel, 551–552
Simulation analysis, 492, 500–501
Single-phase no-growth model, 191
Single-stage constant-growth DCF model, 140
Size-adjusted return (SAR) variable, 64, 71–72, 73–74, 75–76
Size and stock market volatility, 283, 284
Smith, James, 551–552
Source of financing approach to estimating capital, 48–49, 50
S&P 100 option deductions, 427
Special-purpose entities, 370–371
Start-up companies and FEVA model, 237–238
Statement of changes in equity (SCE), 335–337
Stern Stewart EVA, 248
Stewart, G. Bennett, III, 42
Stock. See also Employee stock options;
  illiquid common stock; Stock price performance
  binomial model for, 510–516
  growth, 172, 174
  “high fly”, 172, 173
  intrinsic value of, 243
  new-economy, 255, 296
  overpriced high-P/E, 185
  prices of and accounting earnings, 297–301
  restricted, 288, 454
  unregistered, 279
  using to fund CAPEX, 277
Stockholders:
  aligning interests of employees and, 409
  caveats for EVA, 225
  employee stock options plans and, 413
Stock options. See Options
Stock price performance:
  accounting earnings and, 368
  empirical results, 67–74
  market value added compared to, 77–78
  measures of, 74, 77
  option exercise and, 432–433
  overview of, 62
  quantifying expectations implied by, 185–186
  sample selection, 62–63
  traditional measures results, 67–69
  value-added measures results, 70–74, 75–76
  variables, 63–67
Strategic NPV, 492–493, 506
Stride Rite Corporation, 250–251
Strike price and employee stock options, 411, 445–446
Sunbeam Corporation, 341n25
Sun Microsystems, 423, 490
Supernormal growth periods:
  multistage DCF model and, 140–141
  projections for, 96–97
Swary, Itzhak, 552
Synthetic call options, 512
Tail-hedging strategies, 20
“Talking down” earnings expectations, 296–297
Tax effects of employee stock options:
  on cash flows, 423–427
  forecasting marginal tax rate, 427–428
  overview of, 422–423
Taxes. See also Tax effects of employee stock options
  assumptions of, 539–540
  cash operating, 47–48
  Tax Reform Act of 1996, 422
  Tax shields, present value of, 232
  Technology sector, real options in, 488–491
Terminal phase. See also Franchise valuation under Q-type competition
  growth models in, 205
  overview of, 189–190
Terminal value:
  in discounted cash flow approach, 111–112
  problem of, 245–248, 256
  using constant growth model, 527
Index

Thematic growth trends, 18
Three-stage growth models, 96
Timberland Company, 250–251
Time to expiration in real options valuation, 543
Timing of option exercise, 429–434
Tobin’s \( q \), 38–40, 65, 190, 192
Total stock return (TSR) variable, 63, 71–72, 73–74, 75–76
Tracking error, minimizing, 25
Tracking portfolios, 545
Tradability, assumptions of, 545–547
Traditional performance variables for stock price performance, 64–65, 67–69
Traditional valuation methods. See also
Discounted cash flow (DCF) approach; Price-to-earnings ratio; specific methods
decision tree analysis, 502–504
dividend discount model, 158
economic value added as, 225–226
in fundamental analysis, 164–172
as mathematically equivalent, 229, 239
option valuation, 504–509
price-to-book ratio, 142, 157, 244, 249, 250
price-to-sales ratio, 142, 157–158, 244
purpose of, 156
real options valuation compared to, 494–509
role of beta in, 175
screening uses of, 159–164
sensitivity analysis, 124, 149–150, 492, 499–500, 501
simulation analysis, 492, 500–501
Transaction costs, assumptions of, 539–540
Transactions analysis, 265
Trend analysis in ROE performance, 145–146
TSR (total stock return) variable, 63, 71–72, 73–74, 75–76
Tufano, Peter, 553
Turner, Lynn, 362, 363
Turnover ratios, 353–354
Twin security, 545
Two-phase growth models, 198–204
Two-stage discounted cash flow model, 148

Uncertainty:
cash flows and, 495
lessons from history, 18–19
risk compared to, 2
in valuation, 295
Underlying assets:
as sumptions of, 540
influence on value of, 535–536
market value of, 540–541
nontradability of, 545–551
United Aircraft, 10
Unregistered stock, 279
Unusual items, income from, 312–314
U.S. Federal Reserve, monetary policy of, 21
Valuation date, defining, 260, 264–265
Valuation models, 157, 244–245
Valuation performance, definition of, 389–390
Value, See also Intrinsic value; Terminal value;
Value drivers
creation of, 33–35, 219–222
inputs in, 210
Value-added performance variables for stock price performance, 65–67, 70–74, 75–76
Value-based management, 369
Value drivers:
choices for, 389–390
earnings as, 392–393
earnings compared to cash flow, 402–403
in financial and economic value added model, 235–236
variations among countries in definitions of, 404
Value enhancement models, 209, 227. See also
Economic value added
Value relevance method, 366–368
Vesting dates and option exercise, 432, 469, 472, 473, 475
Volatility:
as sumptions of, 539
cost of capital and, 533
in option-pricing models, 543–544
in real options valuation, 530
Volatility of stock returns:
employee stock option plans and, 439–441
measuring, 282–283
option exercise and, 432
value of options and, 507–508, 509
Voluntary accounting changes, 322
| Voluntary early exercise boundary: comparison of models of | 472–479 |
| heuristic models of | 468–472 |
| overview of | 466–468, 479–480 |
| WACC (weighted-average cost of capital), | 53–54, 57, 82, 266–268, 350 |
| Wal-Mart, 34 |
| Walt Disney Company, 219 |
| Warner Lambert Company, 575 |
| Warranted EV/S (WEVS) values, 253–255 |
| Waxman–Hatch Act of 1984, 116 |
| Wealth creation, measures of, 247 |
| Weighted-average cost of capital (WACC), | 53–54, 57, 82, 266–268, 350 |
| Westinghouse, 10 |
| WEVS (warranted EV/S) values, 253–255 |
| “Whisper forecasts,” 296–297 |
| White, A., 466, 469, 480 |
| Williams, John Burr, 1 |
| Wolverine World Wide, 250–251 |
| XY factor, 6 |
| Yahoo!, 489, 490 |
| Yermack, David, 553 |
Expert perspectives on the latest research and cutting-edge strategies for financial professionals.

Risk management may have been the single most important topic in finance over the past two decades. Leading risk management practitioners provide an in-depth understanding of the theory, philosophy, and critical issues in risk management, from its evolution to the practical aspects and future of managing risk.

High net worth clients demand an array of services and expertise in all areas of financial management, from asset allocation and estate planning to tax-efficient investment strategies and trust management. Stay abreast of the latest with research conducted by leading practitioners and academics from CFA Institute.

Performance analysis has emerged as a central component of effective asset management. Stay up-to-date with the best of CFA Institute publications in investment performance evaluation, which includes all of the related readings used in the CFA Institute Certificate in Investment Performance Measurement (CIPM) program’s "Principles" curriculum.

Available at wiley.com, cfainstitute.org, and wherever books and e-books are sold.

Wiley and the Wiley logo are registered trademarks of John Wiley & Sons, Inc. CFA Institute logo is a registered trademark of CFA Institute.